Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding that the US sales run-rate will improve from H2FY23, and barring COVID-19, sales performance in India continues to be robust. The brokerage firm expects a revenue CAGR of 13 per cent, an EBITDA CAGR of 21 per cent and a PAT CAGR of 28 per cent over FY22-24E.
Q4 results this week: ITC, Sun Pharma, IndusInd Bank, IndiGo, BEL among 81 companies set to announce earnings
India Inc’s Q4 earnings season intensifies with 81 firms, including ITC, Sun Pharma, ONGC, and Hindalco, set to report this week, offering insights into sectoral